![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
First Report of Peginterferon Lambda/Ribavirin in Combination With Either Daclatasvir or Asunaprevir in HCV
Genotype 1 Japanese Patients: Early Sustained Virologic Response (SVR4) Results From the D-LITE Japanese Substudy
|
|
|
Reported by Jules Levin
AASLD
Nov 9-13 2012 Boston
Izumi N,1 Lataillade M,2 Chayama K,3 Toyota J,4 Mochida S,5 Kawada N,6 Ishikawa H,7 Hosokawa E,7 Imai J,7 Scricca R,2 Cohen D,2 Xu D,2 Horga M,2 Yogaratnam J,2 Srinivasan S,2 Kumada H,8 Lopez-Talavera J-C2 for the D-LITE study team
1Musashino-Red Cross Hospital, Tokyo, Japan; 2Bristol-Myers Squibb Research and Development, Wallingford, CT; 3Hiroshima University Hospital, Hiroshima, Japan; 4Sapporo-Kosei General Hospital; 5Saitama Medical University Hospital, Saitama, Japan; 6Osaka City University Hospital; 7Bristol-Myers KK, Tokyo, Japan; 8Toranomon Hospital, Kawasaki, Japan
![AASLD1.gif](../images/111512/111512-5/AASLD1.gif)
![AASLD2.gif](../images/111512/111512-5/AASLD2.gif)
![AASLD3.gif](../images/111512/111512-5/AASLD3.gif)
![AASLD4.gif](../images/111512/111512-5/AASLD4.gif)
![AASLD5.gif](../images/111512/111512-5/AASLD5.gif)
![AASLD6.gif](../images/111512/111512-5/AASLD6.gif)
![AASLD7.gif](../images/111512/111512-5/AASLD7.gif)
![CumWeek4.gif](../images/111512/111512-5/CumWeek4.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|